What is IL1RAPL1 and how does it relate to IL1RAPL1B?

IL1RAPL1 (Interleukin 1 Receptor Accessory Protein Like 1) is a member of the Interleukin-1 receptor protein family with a molecular weight of approximately 80 kDa and 696 amino acid residues in its canonical form. It is primarily localized in the cell membrane and cytoplasm . IL1RAPL1 functions in regulating secretion and presynaptic differentiation through inhibition of N-type voltage-gated calcium channel activity . IL1RAPL1B is considered a variant or isoform of IL1RAPL1, sharing significant structural and functional characteristics while potentially exhibiting tissue-specific expression patterns.

The protein has several synonyms in the literature, including IL1RAPL, MRX10, MRX21, MRX34, OPHN4, TIGIRR-2, X-linked interleukin-1 receptor accessory protein-like 1, and IL1R8 . It is important for researchers to recognize these alternative designations when conducting literature reviews to ensure comprehensive understanding of existing research.

What are the key applications for IL1RAPL1/IL1RAPL1B antibodies in research?

IL1RAPL1 antibodies are primarily utilized in the following experimental applications:

These applications enable researchers to investigate expression patterns, protein interactions, and functional roles of IL1RAPL1/IL1RAPL1B in various experimental contexts .

How should I select the appropriate IL1RAPL1 antibody for my experiment?

Selection of an appropriate IL1RAPL1 antibody should be guided by several key considerations:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, ELISA, ICC, etc.) .

• Species reactivity: Ensure cross-reactivity with your experimental model organism. IL1RAPL1 orthologs have been reported in mouse, rat, bovine, frog, chimpanzee, and chicken species .

• Epitope specificity: Consider whether the antibody targets a specific domain or region of IL1RAPL1. Some antibodies target the C-terminal region, which may be important depending on your research question .

• Monoclonal vs. polyclonal: Monoclonal antibodies offer higher specificity but recognize single epitopes, while polyclonal antibodies provide broader detection but may have higher background.

• Validation evidence: Review literature citations and validation data provided by suppliers to confirm performance in contexts similar to your experimental design .

For research specifically focused on IL1RAPL1B, additional verification of isoform specificity may be necessary.

What are the best practices for validating IL1RAPL1 antibody specificity?

Thorough validation of IL1RAPL1 antibody specificity is critical for generating reliable research data. Recommended validation approaches include:

• Positive and negative controls: Use tissues/cells known to express or lack IL1RAPL1 expression.

• Peptide competition assay: Pre-incubate the antibody with immunizing peptide to confirm binding specificity.

• Knockdown/knockout verification: Compare staining in wildtype versus IL1RAPL1 knockdown/knockout samples.

• Multiple antibody concordance: Verify consistent results using antibodies targeting different epitopes.

• Recombinant protein testing: Use purified recombinant IL1RAPL1 as a positive control.

• Cross-reactivity assessment: Test for potential cross-reactivity with related proteins, particularly other IL-1 receptor family members.

These validation steps should be documented in your experimental methods section to enhance reproducibility and research rigor.

How should I optimize Western blot protocols for IL1RAPL1 detection?

Optimizing Western blot protocols for IL1RAPL1 detection requires attention to several technical factors:

• Sample preparation: IL1RAPL1 is membrane-associated and undergoes glycosylation, requiring efficient extraction with appropriate lysis buffers containing detergents (e.g., RIPA buffer with 1% NP-40 or Triton X-100) .

• Protein denaturation: Due to its transmembrane nature, complete denaturation is essential. Consider including reducing agents and heating samples at 95°C for 5 minutes.

• Gel percentage selection: For the 80 kDa IL1RAPL1 protein, 8-10% acrylamide gels typically provide optimal resolution .

• Transfer optimization: Semi-dry transfer at 15-20V for 30-45 minutes or wet transfer at 30V overnight at 4°C for larger proteins like IL1RAPL1.

• Blocking conditions: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature to minimize background.

• Antibody dilution and incubation: Primary antibody dilutions typically range from 1:500-1:2000, incubated overnight at 4°C. Secondary antibody incubation at 1:5000-1:10000 for 1 hour at room temperature.

• Enhanced detection strategies: Consider using enhanced chemiluminescence (ECL) detection systems with extended exposure times if signal is weak.

What considerations are important for immunohistochemical detection of IL1RAPL1?

Successful immunohistochemical detection of IL1RAPL1 requires optimization of several parameters:

• Fixation method: 4% paraformaldehyde typically preserves IL1RAPL1 epitopes while maintaining tissue architecture.

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes often enhances IL1RAPL1 detection.

• Blocking parameters: Blocking with 5-10% normal serum from the secondary antibody host species reduces non-specific binding.

• Antibody dilution: Typically 1:100-1:500 for primary antibodies, optimized through titration experiments.

• Incubation conditions: Overnight incubation at 4°C generally provides optimal binding with minimal background.

• Detection system selection: Avidin-biotin complex (ABC) or polymer-based detection systems offer enhanced sensitivity for potentially low-abundance proteins like IL1RAPL1.

• Counterstaining considerations: Light hematoxylin counterstaining helps visualize tissue architecture without obscuring specific staining.

How can IL1RAPL1 antibodies be used to investigate neurological disorders?

IL1RAPL1 has significant implications in neurological research due to its role in regulating secretion and presynaptic differentiation . Antibody-based approaches for investigating IL1RAPL1 in neurological contexts include:

• Synaptic localization studies: Immunofluorescence co-localization with synaptic markers to examine IL1RAPL1 distribution at synapses in different neuronal populations.

• Developmental expression profiling: Western blot and immunohistochemical analyses across developmental stages to map temporal expression patterns in the nervous system.

• Mutation impact assessment: Comparing wild-type and mutant IL1RAPL1 localization and processing using epitope-specific antibodies in patient-derived or engineered cell models.

• Protein interaction networks: Co-immunoprecipitation with IL1RAPL1 antibodies to identify novel interaction partners in neuronal contexts.

• Activity-dependent regulation: Using IL1RAPL1 antibodies to assess protein expression and localization changes following neuronal activity modulation.

This approach has proven valuable in understanding IL1RAPL1's contribution to synaptic function and potential role in conditions such as X-linked intellectual disability.

What methodologies can be employed to study IL1RAPL1 interactions with calcium channels?

IL1RAPL1 is believed to regulate secretion and presynaptic differentiation through inhibition of N-type voltage-gated calcium channel activity . Several antibody-based approaches can elucidate these interactions:

• Proximity ligation assay (PLA): Using IL1RAPL1 antibodies in combination with calcium channel antibodies to visualize and quantify direct interactions in situ with single-molecule resolution.

• Co-immunoprecipitation optimization: Sequential or dual immunoprecipitation protocols using cross-linking agents to stabilize potentially transient IL1RAPL1-calcium channel interactions.

• Domain-specific antibodies: Applying antibodies targeting specific IL1RAPL1 domains to identify regions critical for calcium channel interaction.

• Electrophysiological correlation: Combining patch-clamp recordings with immunocytochemistry to correlate IL1RAPL1 expression levels with calcium channel activity in individual neurons.

• FRET-based interaction studies: Using fluorescently-labeled antibodies or fusion proteins to measure proximity between IL1RAPL1 and calcium channel components via Förster resonance energy transfer.

These methodologies provide complementary approaches to understand the molecular mechanisms underlying IL1RAPL1's regulatory effects on calcium channel function.

How do IL1RAPL1 antibodies compare with IL1RAP antibodies in research applications?

While IL1RAPL1 and IL1RAP (IL-1 receptor accessory protein) share some structural similarities as members of the interleukin-1 receptor family, their research applications differ substantially:

Understanding these distinctions is crucial when interpreting research findings and selecting appropriate reagents for specific experimental questions.

What are common challenges in detecting post-translationally modified IL1RAPL1?

IL1RAPL1 undergoes glycosylation as a key post-translational modification , which can present several challenges for antibody-based detection:

• Variable molecular weight: Glycosylation can cause IL1RAPL1 to migrate at different apparent molecular weights in gel electrophoresis, often higher than the predicted 80 kDa .

• Epitope masking: Glycans may obscure antibody binding sites, particularly if antibodies were raised against recombinant proteins with different glycosylation patterns.

• Sample preparation considerations: Enzymatic deglycosylation with PNGase F or Endo H can help standardize detection but may affect antibody recognition depending on epitope location.

• Buffer optimization: Glycoproteins may require specialized extraction conditions to maintain both protein integrity and antibody accessibility.

• Antibody selection strategy: Using antibodies targeting multiple epitopes can help ensure detection regardless of post-translational modification status.

Researchers should consider performing parallel experiments with and without deglycosylation treatment to comprehensively characterize IL1RAPL1 expression patterns.

How can background issues be minimized when using IL1RAPL1 antibodies?

Reducing non-specific background is crucial for obtaining clean, interpretable results with IL1RAPL1 antibodies:

• Antibody validation: Thoroughly validate antibodies using positive and negative controls before experimental application.

• Blocking optimization: Test different blocking agents (BSA, casein, normal serum) and concentrations to identify optimal conditions for your specific sample type.

• Antibody dilution titration: Perform systematic dilution series to identify the optimal concentration that maximizes specific signal while minimizing background.

• Secondary antibody cross-reactivity: Use secondary antibodies pre-adsorbed against serum proteins from your experimental species.

• Incubation conditions: Extending primary antibody incubation time (overnight at 4°C) while reducing concentration often improves signal-to-noise ratio.

• Washing protocol enhancement: Increase the number and duration of washing steps, particularly after primary and secondary antibody incubations.

• Sample preparation refinement: Ensure complete lysis and removal of cellular debris that might cause non-specific binding.

These approaches should be systematically tested and optimized for each specific experimental context.

What strategies can overcome detection challenges in low-expression contexts?

Detecting IL1RAPL1 in systems with low expression levels requires enhanced sensitivity approaches:

• Sample enrichment techniques:

  • Immunoprecipitation before Western blotting

  • Subcellular fractionation to concentrate membrane-associated proteins

  • Cell sorting to isolate specific populations with higher expression

• Signal amplification methods:

  • Tyramide signal amplification (TSA) for immunohistochemistry

  • Enhanced chemiluminescence (ECL) substrates with extended sensitivity for Western blots

  • Biotin-streptavidin amplification systems

• Detection system optimization:

  • Highly sensitive digital imaging systems with extended exposure capabilities

  • Cooled CCD cameras for fluorescence applications

  • Photomultiplier tube (PMT) detection for flow cytometry

• Protocol modifications:

  • Extended primary antibody incubation (48-72 hours at 4°C)

  • Multiple application cycles of primary and secondary antibodies

  • Reduced washing stringency (careful balance with background concerns)

These approaches should be systematically evaluated and optimized for specific experimental contexts to maximize detection sensitivity while maintaining specificity.

How are IL1RAPL1 antibodies contributing to understanding neurodevelopmental disorders?

IL1RAPL1 antibodies have become instrumental in elucidating the molecular mechanisms underlying neurodevelopmental disorders, particularly those involving synaptic dysfunction:

• Expression mapping: Immunohistochemical studies using IL1RAPL1 antibodies have revealed differential expression patterns in specific brain regions during development, providing insight into potential vulnerability to pathological processes.

• Mutation impact analysis: Antibodies recognizing wild-type versus mutant IL1RAPL1 forms have helped characterize trafficking defects and altered protein interactions associated with patient-specific mutations.

• Synaptic localization studies: High-resolution immunofluorescence microscopy with IL1RAPL1 antibodies has demonstrated its precise subcellular localization and co-distribution with other synaptic proteins, revealing potential functional relationships.

• Activity-dependent dynamics: IL1RAPL1 antibodies have enabled the investigation of protein redistribution following neuronal activity, providing insight into its role in experience-dependent synaptic plasticity.

• Interaction partner identification: Immunoprecipitation with IL1RAPL1 antibodies followed by mass spectrometry has expanded the known interactome, revealing novel potential therapeutic targets.

These applications continue to enhance our understanding of IL1RAPL1's role in neural circuit development and function.

What is the relationship between IL1RAPL1 and IL1RAP in signaling pathway research?

Recent research utilizing antibodies against both IL1RAPL1 and IL1RAP has revealed complex relationships between these related molecules:

• Structural similarities and differences: Immunological studies have helped map the domain architectures of IL1RAPL1 and IL1RAP, revealing both conserved and divergent functional regions .

• Differential expression patterns: While IL1RAP is highly expressed in leukemic stem cells but not normal hematopoietic stem cells , IL1RAPL1 shows prominent expression in neural tissues, suggesting tissue-specific functions despite structural similarities .

• Signaling pathway integration: IL1RAP functions as a coreceptor in IL-1, IL-33, and IL-36 signaling systems , while IL1RAPL1 appears more specialized in calcium channel regulation and synaptic differentiation , indicating evolutionary divergence in functional specialization.

• Therapeutic targeting potential: IL1RAP antibodies have shown promising results in targeting leukemic stem cells , whereas IL1RAPL1-targeted therapeutic approaches remain less developed despite potential applications in neurological disorders.

• Cross-reactivity considerations: Due to structural similarities, researchers must carefully validate antibody specificity to avoid cross-reactivity between these related proteins when studying their respective functions.

Understanding these relationships has important implications for both basic research and therapeutic development targeting these pathways.

What emerging applications exist for IL1RAPL1 antibodies beyond traditional immunodetection?

Beyond conventional detection methods, IL1RAPL1 antibodies are finding novel applications in cutting-edge research approaches:

• Super-resolution microscopy: High-affinity IL1RAPL1 antibodies coupled with fluorescent probes are enabling nanoscale visualization of protein organization at synapses using techniques like STORM, PALM, and STED microscopy.

• In vivo imaging applications: Development of near-infrared labeled IL1RAPL1 antibodies or fragments for non-invasive imaging of protein expression in animal models of neurological disorders.

• Antibody-based modulators: Engineering of function-modulating antibodies that can alter IL1RAPL1 activity without cellular depletion, potentially providing new research tools for acute manipulation of signaling.

• Single-cell proteomics: Integration of IL1RAPL1 antibodies into microfluidic platforms for high-throughput analysis of protein expression in individual cells from heterogeneous populations.

• Extracellular vesicle characterization: Application of IL1RAPL1 antibodies to study protein content and membrane organization of neuronal-derived extracellular vesicles as potential biomarkers.

• CRISPR-based tagging: Combined antibody-CRISPR approaches for endogenous tagging and visualization of IL1RAPL1 in living cells to study dynamic regulation.

These emerging applications represent the frontier of IL1RAPL1 research, expanding beyond traditional immunodetection methods to address complex biological questions.